- Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels
- The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats
- The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more
- With its unique product offering, a growing list of patents, and unique market positioning, Lexaria is becoming a key player in the drug delivery technology space
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the completion of its DIAB-A22-1 animal model study, which explored the potential of the patented DehydraTECH(TM)-processed CBD to treat diabetes. Of note were three positive outcomes, including an improvement in general activity, reductions in body weight, and better triglyceride and cholesterol levels.
The study, undertaken by a leading, third-party testing laboratory in Canada, administered select Lexaria “DehydraTECH-CBD 2.0” formulations with doses of either 30 mg/Kg or 100 mg/Kg of body weight. It involved 24 obese and eight lean rats for a total of 32 male Zucker (“ZDF”) rats. As Lexaria’s first study in the diabetes animal model, the company is encouraged by the positive findings. Moreover, it is confident that the results indicate many prospective benefits worthy of further investigation together, possibly with other drugs that help to control glucose levels directly.
Lexaria set out to explore the therapeutic utility of DehydraTECH-CBD against diabetes in November 2022, on the heels of the success of its clinical studies on hypertension. The company’s management was optimistic that the results from the hypertension study would be replicated in the diabetes study, given that hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes.
The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore DehydraTECH’s application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more. With DehydraTECH having proven to increase the effectiveness and the way active pharmaceutical ingredients enter the bloodstream, Lexaria is exploring its full potential for improving consumer products. Its efforts have seen the company awarded 28 patents, with more patents pending worldwide.
Diabetes is the 7th largest cause of death in the United States and accounts for an estimated value of $26.7 billion in the global diabetes devices market. Lexaria’s management is hopeful that its current efforts and studies will inch the company closer to taking advantage of this industry’s market potential. In 2021, the global diabetes drug market was estimated at $63.1 billion and is projected to hit $80.65 billion by 2027. With the company’s unique technology, a growing list of patents, and unique market positioning, Lexaria is set to capitalize on this growth and become a leader in the drug delivery technology space.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX